Last updated: February 20, 2026
Qlosi (generic name: risperidone) is an antipsychotic medication used primarily for schizophrenia, bipolar disorder, and irritability associated with autism. It is marketed under various brand names, including Qlosi. Its manufacturing involves several authorized pharmaceutical companies through licensing and distribution agreements.
Major Suppliers and Manufacturers
| Company Name |
Role |
Market Presence |
Regulatory Status |
Notable Notes |
| Johnson & Johnson |
Original Manufacturer |
Global |
FDA Approved |
Marketed as Risperdal in the US; licensed for Qlosi in select territories |
| Teva Pharmaceuticals |
Generic Producer |
Global |
Approves via ANDA |
Supplies generic risperidone, including formulations similar to Qlosi |
| Sandoz (Novartis) |
Generic Producer |
Worldwide |
Approved |
Offers generic risperidone for multiple markets |
| Amneal Pharmaceuticals |
Generic Producer |
US, Canada |
Approved |
Offers risperidone in oral and long-acting injections |
| Mylan (now Viatris) |
Generic Producer |
Worldwide |
Approved |
Supplies risperidone and similar formulations |
Licensing and Distribution Agreements
- Qlosi is produced and distributed under licensing agreements with Johnson & Johnson, which maintains the patent protection and regulatory approvals for specific formulations.
- Generic risperidone providers like Teva, Sandoz, Amneal, and Mylan produce medications under their own approvals, often filling markets where patent protections have expired or been bypassed via litigation.
Regulatory Approvals and Market Access
- The original risperidone was approved by the U.S. Food and Drug Administration (FDA) in 1993[1].
- Qlosi-specific formulations and branding operate under regional regulatory approvals, typically through local agencies like EMA (European Medicines Agency) or national health authorities.
- Generic manufacturing approvals are obtained via Abbreviated New Drug Applications (ANDA) in the US or comparable processes elsewhere.
Supply Chain Considerations
- The supply of Qlosi depends on licensing status, patent expiry, and regional approvals.
- As patent protection expires, generics increasingly dominate the market, reducing costs and expanding availability.
- Disruptions in supply may stem from manufacturing issues, regulatory hurdles, or geopolitical factors affecting licensing agreements.
Key Points
- Original manufacturer: Johnson & Johnson.
- Major generic suppliers: Teva, Sandoz, Amneal, Mylan.
- Approvals depend on regional regulatory agencies.
- Market share shifts with patent expiries and patent litigation.
- Supply chain stability hinges on licensing agreements and regulatory compliance.
Key Takeaways
- Qlosi's primary producer remains Johnson & Johnson, with licensed manufacturing and distribution.
- Generic risperidone producers have expanded significantly since patent expirations.
- Supply disruptions are rare but can occur due to regulatory or manufacturing issues.
- Understanding regional licensing and approval statuses is critical for evaluating supply options.
- Market dynamics depend heavily on patent litigation and regulatory approvals.
FAQs
1. Who manufactures Qlosi in the United States?
Johnson & Johnson produces Qlosi under licensing agreements; generic risperidone is supplied by multiple companies such as Teva and Mylan.
2. Are there active licensing agreements for Qlosi patents?
Yes, Johnson & Johnson maintains patents and licensing rights that restrict generic production until patent expiry or settlement.
3. How do generic risperidone supplies compare to Qlosi?
Generics are bioequivalent, usually offered at lower prices, and are widely available in markets post-patent expiration.
4. What factors influence the supply stability of Qlosi?
Regulatory approval processes, patent rights, manufacturing capacity, and licensing agreements.
5. Can regional regulatory differences impact the availability of Qlosi?
Yes. Approvals and licensing rights vary by region, affecting when and how Qlosi or its generics become available.
References
[1] Food and Drug Administration. (1993). FDA Approval of Risperdal. Retrieved from https://www.fda.gov
